Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avila Therapeutics has concluded patient dosing in the first cohort of a multiple dose escalation Phase 1b trial evaluating AVL-292 in patients with B cell cancer malignancies including B-cell non-hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL).
Subscribe to our email newsletter
In two Phase 1a studies, AVL-292 demonstrated a favorable safety, tolerability and pharmacokinetic profile in healthy volunteers.
The trial is investigating the pharmacokinetics, safety and tolerability profile of VL-292 as monotherapy in 28-day cycles in subjects with relapsed and/or refractory B-NHL, CLL and Waldenstrom’s Macroglobulinemia.